FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975140915> ?p ?o ?g. }

• W2975140915 endingPage "3873" @default.
• W2975140915 startingPage "3864" @default.
• W2975140915 abstract "Crizotinib has been the standard treatment for patients with anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). It demonstrated superior progression-free survival (PFS) and higher objective response rates (ORRs) vs. chemotherapy in previously treated and untreated patients with ALK-positive advanced NSCLC. This retrospective analysis reports real-world experience in treatment outcome and toxicity of crizotinib in this group of patients, with a focus on the cardiac toxicity and its management.Twenty-two patients diagnosed with ALK-positive NSCLC, either by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), treated at Johns Hopkins Singapore International Medical Centre (JHSIMC) and Tan Tock Seng Hospital (TTSH) in Singapore, were identified and followed for a median of 18 months. Data were collected and analyzed for baseline demographics, PFS, ORR, duration of response, toxicity and overall survival (OS).Clinical profile of patients included in the study was similar with clinical trials on crizotinib. Most patients were young of mean age 42, non-smokers and with good performance status. Fifty-nine percent had prior chemotherapy. Fifty percent of patients had brain metastases (BM), either de novo or on progression. ORR of crizotinib was 64% with median total duration of treatment of 8.5 months (range, 2-73+ months). Median PFS for patients treated with first-line crizotinib was 15 months. Most patients with BM had brain radiation. Median time for intracranial progression from the start of crizotinib was 11 months. Those with stable or responding extracranial disease continued crizotinib after radiotherapy to the brain. Median duration of response in this group of patients was 14 months (range, 2-31 months). Median OS among patients treated with upfront crizotinib was not reached, with 7 out of 11 patients still alive at the time of data analysis (n=11, range, 1-73+). Toxicity was manageable with moderate rate of grade 3 or worse toxicity (n=7, 31.8%). Three patients had grade 3-4 neutropenia. Eighteen percent (n=4) of patients developed cardiotoxicities such as bradycardia, prolonged QTc interval and complete heart block. One patient who developed complete heart block required pacemaker insertion. Two patients are long term responders who have been on crizotinib for 68+ and 73+ months.This retrospective analysis of a real-world experience confirms the therapeutic benefit of crizotinib in advanced ALK-positive NSCLC. Our data showed crizotinib is tolerable and effective, comparable with literature report. Occasional serious cardiac toxicity requires attention." @default.
• W2975140915 created "2019-10-03" @default.
• W2975140915 creator A5008114425 @default.
• W2975140915 creator A5070356563 @default.
• W2975140915 date "2019-09-01" @default.
• W2975140915 modified "2023-10-01" @default.
• W2975140915 title "Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer" @default.
• W2975140915 cites W1515180961 @default.
• W2975140915 cites W1964973266 @default.
• W2975140915 cites W1970261657 @default.
• W2975140915 cites W1970299210 @default.
• W2975140915 cites W1990626198 @default.
• W2975140915 cites W2011670622 @default.
• W2975140915 cites W2031387869 @default.
• W2975140915 cites W2050249255 @default.
• W2975140915 cites W2055402151 @default.
• W2975140915 cites W2099530756 @default.
• W2975140915 cites W2103633410 @default.
• W2975140915 cites W2107679713 @default.
• W2975140915 cites W2111254482 @default.
• W2975140915 cites W2111724182 @default.
• W2975140915 cites W2116478428 @default.
• W2975140915 cites W2151116840 @default.
• W2975140915 cites W2151620138 @default.
• W2975140915 cites W2229131726 @default.
• W2975140915 cites W2404591169 @default.
• W2975140915 cites W2415409512 @default.
• W2975140915 cites W2560284840 @default.
• W2975140915 cites W2581996620 @default.
• W2975140915 cites W2613260339 @default.
• W2975140915 cites W2803802743 @default.
• W2975140915 doi "https://doi.org/10.21037/jtd.2019.09.15" @default.
• W2975140915 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6790458" @default.
• W2975140915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31656659" @default.
• W2975140915 hasPublicationYear "2019" @default.
• W2975140915 type Work @default.
• W2975140915 sameAs 2975140915 @default.
• W2975140915 citedByCount "10" @default.
• W2975140915 countsByYear W29751409152019 @default.
• W2975140915 countsByYear W29751409152020 @default.
• W2975140915 countsByYear W29751409152021 @default.
• W2975140915 countsByYear W29751409152022 @default.
• W2975140915 countsByYear W29751409152023 @default.
• W2975140915 crossrefType "journal-article" @default.
• W2975140915 hasAuthorship W2975140915A5008114425 @default.
• W2975140915 hasAuthorship W2975140915A5070356563 @default.
• W2975140915 hasBestOaLocation W29751409151 @default.
• W2975140915 hasConcept C117643217 @default.
• W2975140915 hasConcept C126322002 @default.
• W2975140915 hasConcept C141071460 @default.
• W2975140915 hasConcept C143998085 @default.
• W2975140915 hasConcept C2776232967 @default.
• W2975140915 hasConcept C2776256026 @default.
• W2975140915 hasConcept C2776694085 @default.
• W2975140915 hasConcept C2778347629 @default.
• W2975140915 hasConcept C2779422266 @default.
• W2975140915 hasConcept C2780739268 @default.
• W2975140915 hasConcept C509974204 @default.
• W2975140915 hasConcept C71924100 @default.
• W2975140915 hasConceptScore W2975140915C117643217 @default.
• W2975140915 hasConceptScore W2975140915C126322002 @default.
• W2975140915 hasConceptScore W2975140915C141071460 @default.
• W2975140915 hasConceptScore W2975140915C143998085 @default.
• W2975140915 hasConceptScore W2975140915C2776232967 @default.
• W2975140915 hasConceptScore W2975140915C2776256026 @default.
• W2975140915 hasConceptScore W2975140915C2776694085 @default.
• W2975140915 hasConceptScore W2975140915C2778347629 @default.
• W2975140915 hasConceptScore W2975140915C2779422266 @default.
• W2975140915 hasConceptScore W2975140915C2780739268 @default.
• W2975140915 hasConceptScore W2975140915C509974204 @default.
• W2975140915 hasConceptScore W2975140915C71924100 @default.
• W2975140915 hasIssue "9" @default.
• W2975140915 hasLocation W29751409151 @default.
• W2975140915 hasLocation W29751409152 @default.
• W2975140915 hasLocation W29751409153 @default.
• W2975140915 hasLocation W29751409154 @default.
• W2975140915 hasOpenAccess W2975140915 @default.
• W2975140915 hasPrimaryLocation W29751409151 @default.
• W2975140915 hasRelatedWork W2318061299 @default.
• W2975140915 hasRelatedWork W2400744927 @default.
• W2975140915 hasRelatedWork W2516942920 @default.
• W2975140915 hasRelatedWork W2624310346 @default.
• W2975140915 hasRelatedWork W2811223828 @default.
• W2975140915 hasRelatedWork W2941535758 @default.
• W2975140915 hasRelatedWork W2982087753 @default.
• W2975140915 hasRelatedWork W3197633853 @default.
• W2975140915 hasRelatedWork W3199005851 @default.
• W2975140915 hasRelatedWork W2970177775 @default.
• W2975140915 hasVolume "11" @default.
• W2975140915 isParatext "false" @default.
• W2975140915 isRetracted "false" @default.
• W2975140915 magId "2975140915" @default.
• W2975140915 workType "article" @default.